According to the website of the National Healthcare Security Administration on the 17th, the National Joint Procurement Office for Drugs issued the "Announcement on Cancelling the Qualification of Sichuan Haimeng Zhisen Biopharmaceutical Co., Ltd. for Phloroglucinol Injection and Listing the Company and the Product Manufacturer Taiji Group Sichuan Taiji Pharmaceutical Co., Ltd. on the Violation List" on the 17th.

The announcement shows that the phloroglucinol injection produced by Sichuan Haimeng Zhisen Biopharmaceutical Co., Ltd. on behalf of Taiji Group Sichuan Taiji Pharmaceutical Co., Ltd. is the selected drug in the tenth batch of national centralized drug procurement, which has not yet been implemented.

According to the supervision and inspection notice issued by the Sichuan Provincial Drug Administration on March 17, 2025, the holder Sichuan Haimeng Zhisen Biopharmaceutical Co., Ltd. failed to effectively monitor the production process of the entrusted production enterprise, and the entrusted production enterprise Taiji Group Sichuan Taiji Pharmaceutical Co., Ltd. had deviations in the key production process of some batches of products, and did not carry out deviation processing according to the specification requirements. The comprehensive assessment conclusion was that it did not meet the requirements of the Good Manufacturing Practice (GMP) for pharmaceutical production. The drug supervision department has suspended the production of phloroglucinol injection by Taiji Group Sichuan Taiji Pharmaceutical Co., Ltd. and the listing and sale of phloroglucinol injection by Sichuan Haimeng Zhisen Biopharmaceutical Co., Ltd. At the same time, the Joint Procurement Office decided to cancel the selection qualification of phloroglucinol injection by Sichuan Haimeng Zhisen Biopharmaceutical Co., Ltd., and at the same time included Sichuan Haimeng Zhisen Biopharmaceutical Co., Ltd. and Taiji Group Sichuan Taiji Pharmaceutical Co., Ltd. in the "violation list", suspending the application qualifications of the two companies to participate in the national organized drug centralized procurement activities from March 18, 2025 to September 17, 2026.

https://finance.eastmoney.com/a/202503183349003369.html